China News Service, Shanghai, March 22 (Reporter Chen Jing) China is one of the countries with the highest incidence of bile duct cancer in the world.
The reporter learned on the 22nd that in the future, Chinese patients with cholangiocarcinoma and acute myeloid leukemia will have innovative and precise treatment options.
The reporter learned on the 22nd that the first prescription of Avonib (Tushuwo?) has been approved by the State Drug Administration of China, and the first prescription has been issued in Boao Super Hospital, and the first patient has been successfully administered.
"Patients with cholangiocarcinoma often face high malignancy, difficult treatment and low survival rate. Patients with IDH1-mutant cholangiocarcinoma, especially those whose disease progresses after chemotherapy, urgently need new treatment options." Boao Super Hospital Li Jiangfeng, director of the Digestive Center, told reporters on the same day: "Avonib is the world's first precision targeted drug approved for the treatment of patients with IDH1-mutated cholangiocarcinoma, which can significantly improve the progression-free survival of patients. Cholangiocarcinoma patients offer new treatment options."
It is reported that ivonib tablets (Tosuvo?) is used to treat adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations.
In February this year, Avonib was approved to be used in urgent clinical needs in the Boao Super Hospital, a specific medical institution in the Lecheng International Medical Tourism Pilot Zone in Boao, Hainan, China, benefiting cholangiocarcinoma patients at the same time as the world.
It is understood that in terms of drug accessibility and affordability, Avnib has made many progress. As one of 75 overseas special drugs, it has been included in Beijing Pratt & Whitney Health Insurance, and it is also one of 25 domestic drugs. Included in Hainan Lecheng Global Special Drug Insurance, etc.
(over)